UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Teva Pharmaceutical Industries Ltd. |
||||
(Translation of registrants name into English) | ||||
Israel | ||||
(Jurisdiction of incorporation or organization) | ||||
5 Basel Street, P.O. Box 3190 Petach Tikva 49131 Israel |
||||
(Address of principal executive office) |
||||
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [x] Form 20-F [ ] Form 40-F | ||||
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ] | ||||
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ] | ||||
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [ ] Yes [x] No | ||||
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
Teva Pharmaceutical Industries Ltd. | ||
Date: 07/25/2013 | By: |
Eyal Desheh |
Name: | Eyal Desheh | |
Title: | Chief Financial Officer | |
Exhibit No. | Description | |
|
|
|
99.1 | Teva and Lonza Announce Mutual Decision to Discontinue Biologics Joint Venture | |
![]() ![]() |
Teva and Lonza Announce Mutual Decision to Discontinue Biologics Joint Venture
| Teva to Pursue Its Biologics Strategy to Create a Balanced Portfolio of Biosimilars, Biobetters and Innovative Biologics. |
| Lonza to Focus on Core Expertise in Contract Manufacturing and Cell Line Development and Ceases Investing in Non-Strategic Areas. |
Jerusalem and Basel, Switzerland, July 25, 2013 Teva Pharmaceutical Industries (NYSE: TEVA) and Lonza Group (LONN: SIX) today announced that following a strategic review of the Teva-Lonza Joint Venture (TL-JV), the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars. The discontinuation of the TL-JV, which began in 2009, will enable both companies to better advance their own strategies and efforts in serving those healthcare communities. Both companies will continue to explore opportunities to maximize the value of the investments and progress that the joint venture has made to this point, and remain in agreement that affordable, efficacious and safe biosimilar treatments will bring benefits to patients and better serve these communities.
Dr. Michael Hayden, President, Global R&D and CSO of Teva stated that Teva has a track record of success in the biologics arena and we plan to continue and build on that success. This decision supports our ability to maintain a highly selective approach in our efforts to create a balanced portfolio of biosimilars, biobetters and innovative biologics that align with our overall portfolio and areas of disease focus, and by doing so better support our patients in these areas.
Dr. Stephan Kutzer, COO of Lonza Pharma & Biotech Market Segment stated that With the discontinuation of the joint venture we will cease investing in areas that are not strategic to Lonza such as clinical developments and end product commercialization. In our assessment those investments in biosimilar will require more capital than initially planned and will also take more time until they reach the market. This is why we intend in the future to limit our role by focusing on our core expertise in the areas of contract manufacturing and cell line development.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company,
committed to increasing access to high-quality healthcare by developing, producing and
marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and
active pharmaceutical ingredients. Headquartered in Israel, Teva is the worlds leading
generic drug maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Tevas branded businesses focus on CNS, oncology,
pain, respiratory and womens health therapeutic areas as well as biologics. Teva currently
employs approximately 46,000 people around the world and reached $20.3 billion in net
revenues in 2012.
About Lonza
Lonza is one of the worlds leading suppliers to the pharmaceutical, healthcare and life
science industries. Products and services span its customers needs from research to final
product manufacture. It is the global leader in the production and support of chemical and
biological active pharmaceutical ingredients. Biopharmaceuticals are one of the key growth
drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in
large and small molecules, peptides, amino acids and niche bioproducts which play an
important role in the development of novel medicines and healthcare products. Lonza is also
the world leader in microbial control providing innovative, chemistry-based and related
solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its
activities encompass the areas of water treatment, personal care, health and hygiene,
industrial preservation, materials protection, and wood treatment. In addition, Lonza is a
leader in cell-based research, endotoxin detection and cell therapy manufacturing.
Furthermore, the company is a leading provider of value chemical and biotech ingredients to
the nutrition and agro markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (SGX-ST). In 2012, the company had sales of CHF 3925 million. Further information can be found at www.lonza.com.
Tevas Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and
expectations of management. Such statements are based on managements current beliefs and
expectations and involve a number of known and unknown risks and uncertainties that could
cause our future results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize additional pharmaceutical
products, including our ability to develop, manufacture, market and sell biopharmaceutical
products, competition for our innovative products, especially Copaxone® (including
competition from innovative orally-administered alternatives, as well as from potential
purported generic equivalents), competition for our generic products (including from other
pharmaceutical companies and as a result of increased governmental pricing pressures),
competition for our specialty pharmaceutical businesses, our ability to achieve expected
results through our specialty, including innovative, R&D efforts, the effectiveness of our
patents and other protections for innovative products, decreasing opportunities to obtain
U.S. market exclusivity for significant new generic products, our ability to identify,
consummate and successfully integrate acquisitions, the effects of increased leverage as a
result of recent acquisitions, the extent to which any manufacturing or quality control
problems damage our reputation for high quality production and require costly remediation,
our potential exposure to product liability claims to the extent not covered by insurance,
increased government scrutiny in both the U.S. and Europe of our agreements with brand
companies, potential liability for sales of generic products prior to a final resolution of
outstanding patent litigation. our exposure to currency fluctuations and restrictions as
well as credit risks, the effects of reforms in healthcare regulation and pharmaceutical
pricing and reimbursement, any failures to comply with complex Medicare and Medicaid
reporting and payment obligations, governmental investigations into sales and marketing
practices (particularly for our specialty pharmaceutical products), uncertainties
surrounding the legislative and regulatory pathways for the registration and approval of
biotechnology-based products, adverse effects of political or economical instability,
corruption, major hostilities or acts of terrorism on our significant worldwide operations,
interruptions in our supply chain or problems with our information technology systems that
adversely affect our complex manufacturing processes, any failure to retain key personnel or
to attract additional executive and managerial talent, the impact of continuing
consolidation of our distributors and customers, variations in patent laws that may
adversely affect our ability to manufacture our products in the most efficient manner,
potentially significant impairments of intangible assets and goodwill, potential increases
in tax liabilities, the termination or expiration of governmental programs or tax benefits,
environmental risks and other factors that are discussed in our Annual Report on Form 20-F
for the year ended December 31, 2012 and in our other filings with the U.S. Securities and
Exchange Commission. Forward-looking statements speak only as of the date on which they are
made and the Company undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise.
Further Information:
Teva
IR Contacts: | Kevin C. Mannix
|
United States | (215) 591-8912 | |||
Ran Meir
|
United States | (215) 591-3033 | ||||
Tomer Amitai
|
Israel | 972 (3) 926-7656 | ||||
PR Contacts: | Iris Beck Codner
|
Israel | 972 (3) 926-7246 | |||
Denise Bradley
|
United States | (215) 591-8974 |
Lonza
Corporate Communications | Investor Relations | Media Relations | ||
Dominik Werner
|
Dirk Oehlers | Melanie Disa | ||
Tel +41 61 316 8798
|
Tel +41 61 316 8540 | Tel +1 201 316 9413 | ||
dominik.werner@lonza.com
|
dirk.oehlers@lonza.com | melanie.disa@lonza.com | ||
###